Pathos
Oncology Therapeutics · Drug Discovery AI
$365Mtotal raised · 3 rounds on record
4open roles
$283Mlatest round · Venture round · Apr 2025 · 18 mo ago
2backers · Cota Capital, NEA
Overview
Pathos integrates AI technology, biological modeling, and the largest collection of oncology patient data to make clinical trials smarter and more precise.
Funding and backers
Total raised
$365M
3 rounds on record
Latest round
$283M
Venture round · Apr 2025 · 18 mo ago
Team
8
US Form 5500 (plan participants) · May 2025
Hiring now
5
+1 posted in 30 days
Backers
2
Cota Capital, NEA
The money's age
Due for its next round
18 months since the last round · and hiring
Momentum
23/100
hiring for its size, in the news
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 17, 2025
Raised a round Venture round $283M · SEC Form D
Oct 24, 2024
Raised a round Venture round $62M · SEC Form D
May 23, 2023
Launched Pathos Launches Precision Oncology Pipeline With License of First Phase I Program, a CBP/p300 Inhibitor · pathos.com
Mar 2, 2023
New executive Eric Lefkofsky, Executive Officer, Director · SEC Form D
Feb 17, 2023
Raised a round Venture round $20M · SEC Form D
2022
Founded
Tractionpublic signals, read monthly
Web presence
top 2%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Apr 2025 | $283M | — | SEC Form D |
| Venture round | Oct 2024 | $62M | — | SEC Form D |
| Venture round | Feb 2023 | $20M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Pathos AI, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Ryan FukushimaExecutive Officer, DirectorSEC Form D
Alex DolanExecutive OfficerSEC Form D
Andrew HeinleinExecutive OfficerSEC Form D
Eric LefkofkyExecutive Officer, DirectorSEC Form D
Eric LefkofskyExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Let's talk Our team will contact you and share more about our offerings. About Us QuantHealth is the global leader in AI-driven, clinical…
Cure51 collects and analyses the biological data of exceptional cancer survivors to find what made their outcome possible. Its platform…
A comprehensive platform for care that happens between visits, Canopy enhances patient care, improves clinical workflows, and generates new…
Alterome is a clinical-stage precision oncology company developing first-in-class, alteration-specific therapies for AKT E17K- and…
ETX-19477 is a selective PARG inhibitor designed to address DNA damage response vulnerabilities and expand precision treatment options for…
Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The…
Jobs
≈ $209k – $364k per year (Estimated) · In office · Full-Time · 10+ years exp · Bachelor's Degree · New York
Multimodal AI
AI Agents
DevOps
GCP
Apply
≈ $174k – $345k per year (Estimated) · In office · Full-Time · 8+ years exp · New York
Python
TypeScript
Google BigQuery
AI/ML
LangGraph
LangChain
Model Context Protocol
Multimodal AI
AI Agents
LLM
Knowledge Graph
DevOps
GCP
Apply
≈ $128k – $245k per year (Estimated) · In office · Full-Time · 6+ years exp · New York
Python
TypeScript
Model Context Protocol
Multimodal AI
AI Agents
LLM
Knowledge Graph
LLM Guardrails
DevOps
Terraform
GCP
Azure
CI/CD
AWS
Kubernetes
Google GKE
IAM
Cybersecurity
HIPAA
Apply
≈ $204k – $355k per year (Estimated) · In office · Full-Time · 8+ years exp · PhD · New York
Multimodal AI
AI Agents
Life Sciences
GMP
Apply
Visa sponsorship
1
H-1B filings in 12 months
$403k
Median offered salary
5
Open roles in United States
Who they sponsor
Computer and information research scientists
1
In the register as Pathos AI, Inc., Chicago, IL
Other sponsors in the same field
Outpacebio
Eli Lilly and Company 
Regeneron Pharmaceuticals 
AbbVie
See 5 open roles Alert me
US Department of Labor · latest filing Sep 15, 2025 · Visa details by country
Growth
Hiring Momentum
62/100
Growing
Open positions
5
1 opened / 4 closed in 30 days
Median time-to-fill
84 days
faster than 14% of the market
ATS activity
Every ~4 hours
Today
Hiring Dynamics
+100%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Biotech
29% ▼
AI/ML
14% ▼
Security
14% ▼
Administrative
14% ▼
Finance
14% ▲
Science & Research
14% ▼
Activity Timeline
Added QuickBooks to stack
Oct 2026
Added Microsoft Excel to stack
Oct 2026
Added Kubernetes to stack
Oct 2026
Added Google GKE to stack
Oct 2026
Added GMP to stack
Oct 2026
Added Machine Learning to stack
Sep 2026
People
Ryan Fukushima
Executive Officer, Director
Alex Dolan
Executive Officer
Andrew Heinlein
Executive Officer
Eric Lefkofky
Executive Officer, Director
Eric Lefkofsky
Executive Officer, Director
Mohamad Makhzoumi
Director
Tyrell Rivers
Director
Amit Mehta
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Tech stack
Technologies named in job postings at Pathos over the last 12 months, by layer, with the share of postings for each.
Technologies in use
26
Postings analysed
9
Stack modernity
89/100AI adopter
Languages
Python
TypeScript
Frameworks & libraries
LangGraph
LangChain
Databases
Google BigQuery
Cloud & platforms
GCP
AWS
Azure
Google GKE
AI & ML
LLM
ChatGPT
Claude
Sign in to see how your skills match this stack
Sign In
Full Pathos tech stack
26 technologies · by team · pay by technology · changes · similar stacks
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Cota CapitalVia a fund
NEAVia a fund
672 portfolio companies
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Pathos Communications: H1 Revenue Rises 14% To $7.3 Million As Adjusted EBITDA Jumps 36%
Pathos Communications reported first-half 2026 revenue of $7.3 million, up 14% year over year, while adjusted EBITDA increased 36% to $1.7 million as the PR technology company expanded its product offering, sales organization and geographic reach.
Read more
Report
Pathos AI signs two cancer deals with Alphamab and AZ
Pathos AI has grown its oncology pipeline by licensing a bispecific ADC from Alphamab for $125m and partnering a breast cancer drug from AstraZeneca.
Read more
Report
Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC
NEW YORK, August 3rd, 2026 (GLOBE NEWSWIRE) - Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, today announced a licensing agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
Read more
Report
Pathos AI Enters Collaboration and Co-Exclusive Licensing Agreement to Advance Novel ERα PROTAC for ER+ Breast Cancer into the Clinic
Pathos assumes responsibility for early clinical development of AZD4241, utilizing its AI-driven Foundry platform to drive patient stratification and trial design.
NEW YORK, August 4th, 2026 (GLO
Read more
Report
Pathos AI Acquires Majority Stake in DeuterOncology to Advance Next-Generation MET Inhibitor Identified by Pathos Foundry Platform
Read more
Report
Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
Read more
Report
AI-powered drug development startup Pathos AI closes $365M investment
AI-powered drug development startup Pathos AI closes $365M investment - SiliconANGLE
Read more
Report
Pathos AI Appoints Iker Huerga as Chief Executive Officer to Lead the Next Era of AI-Enabled Drug Development
New York, NY, May 8th, 2025 (GLOBE NEWSWIRE) - Pathos AI, (www.pathos.com), a leading AI-enabled biotech company focused on transforming drug development in oncology, today announced the appointment of Iker Huerga as Chief Executive Offi
Read more
Report
AstraZeneca joins Tempus, Pathos in cancer AI project
AstraZeneca has started work with Tempus and Pathos AI on a $200m project to build a comprehensive multimodal foundation model for oncology.
Read more
Report
Pathos Signs Strategic Agreements with AstraZeneca and Tempus to Develop the Largest Multimodal Foundation Model in Oncology
CHICAGO, April 23, 2025 - Pathos AI, Inc.(www.pathos.com), a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, today announced multi-year, strategic collaborations with Astra
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
New York
New York
United States
HQ
5 open roles 7 posted in 90 days 40% engineering 50-200 est. staff
hires for Biotech, AI/ML, Security